

Huilin Huang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8430026/publications.pdf>

Version: 2024-02-01

30
papers

7,499
citations

361413
20
h-index

552781
26
g-index

33
all docs

33
docs citations

33
times ranked

6139
citing authors

#	ARTICLE	IF	CITATIONS
1	N(6)-methyladenosine-binding protein YTHDF1 suppresses EBV replication and promotes EBV RNA decay. <i>EMBO Reports</i> , 2021, 22, e50128.	4.5	59
2	N ⁶ -methyladenosine Steers RNA Metabolism and Regulation in Cancer. <i>Cancer Communications</i> , 2021, 41, 538-559.	9.2	24
3	Structural and functional characterization of multiple myeloma associated cytoplasmic poly(A) polymerase FAM46C. <i>Cancer Communications</i> , 2021, 41, 615-630.	9.2	7
4	Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC. <i>Haematologica</i> , 2020, 105, 148-160.	3.5	41
5	RNA Modifications in Cancer: Functions, Mechanisms, and Therapeutic Implications. <i>Annual Review of Cancer Biology</i> , 2020, 4, 221-240.	4.5	60
6	The Biogenesis and Precise Control of RNA m6A Methylation. <i>Trends in Genetics</i> , 2020, 36, 44-52.	6.7	198
7	miR-550-1 functions as a tumor suppressor in acute myeloid leukemia via the hippo signaling pathway. <i>International Journal of Biological Sciences</i> , 2020, 16, 2853-2867.	6.4	11
8	RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia. <i>Cell Stem Cell</i> , 2020, 27, 64-80.e9.	11.1	225
9	Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. <i>Cancer Cell</i> , 2020, 38, 79-96.e11.	16.8	389
10	m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. <i>Cancer Cell</i> , 2020, 37, 270-288.	16.8	688
11	Histone H3 trimethylation at lysine 36 guides m6A RNA modification co-transcriptionally. <i>Nature</i> , 2019, 567, 414-419.	27.8	452
12	IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner. <i>Nucleic Acids Research</i> , 2019, 47, 375-390.	14.5	256
13	RNA N ⁶ -Methyladenosine Modification in Normal and Malignant Hematopoiesis. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1143, 75-93.	1.6	35
14	TET1 Modulates DNA Replication in Leukemia Cells Via a Catalytic-Independent Mechanism through Cooperating with KAT8. <i>Blood</i> , 2019, 134, 1249-1249.	1.4	0
15	Recognition of RNA N ⁶ -methyladenosine by IGF2BP proteins enhances mRNA stability and translation. <i>Nature Cell Biology</i> , 2018, 20, 285-295.	10.3	1,650
16	RNA N ⁶ -methyladenosine modification in cancers: current status and perspectives. <i>Cell Research</i> , 2018, 28, 507-517.	12.0	586
17	METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification. <i>Cell Stem Cell</i> , 2018, 22, 191-205.e9.	11.1	749
18	R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling. <i>Cell</i> , 2018, 172, 90-105.e23.	28.9	794

#	ARTICLE	IF	CITATIONS
19	N6-Methyladenosine Modification Regulates Cell Metabolism in Acute Myeloid Leukemia. Blood, 2018, 132, 880-880.	1.4	0
20	ALKBH5 Functions As an Oncogene in Acute Myeloid Leukemia. Blood, 2018, 132, 3910-3910.	1.4	0
21	ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia. Scientific Reports, 2017, 7, 1853.	3.3	26
22	FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine RNA Demethylase. Cancer Cell, 2017, 31, 127-141.	16.8	1,139
23	Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia. Nature Communications, 2017, 8, 2099.	12.8	45
24	Targeted Inhibition of STAT/TET1 Axis As a Potent Therapeutic Strategy for Acute Myeloid Leukemia. Blood, 2017, 130, 857-857.	1.4	1
25	The N6-Adenine Methyltransferase METTL14 Plays an Oncogenic Role in Acute Myeloid Leukemia. Blood, 2016, 128, 1536-1536.	1.4	1
26	Fto Plays an Oncogenic Role in Acute Myeloid Leukemia As a N6-Methyladenosine RNA Demethylase. Blood, 2016, 128, 2706-2706.	1.4	5
27	TET1 Regulates DNA Replication through Targeting of Minichromosome Maintenance Genes. Blood, 2016, 128, 2687-2687.	1.4	0
28	Alox5 Functions As Both Tumor Suppressor and Drug Sensitizer in AML. Blood, 2016, 128, 2851-2851.	1.4	0
29	Uncover TET1 Targets in MLL-Rearranged Leukemia. Blood, 2015, 126, 3632-3632.	1.4	0
30	Mircrona-550 Functions As a Critical Tumor Suppressor in Acute Myeloid Leukemia. Blood, 2015, 126, 1240-1240.	1.4	0